For Physicians

Text

Other Pipeline

In addition to our product candidates Custirsen in Phase 3 development, and OGX-427 in Phase 2 development, our product pipeline is comprised of the following molecule:

OGX-225

: OGX-225 is a second generation antisense drug designed to inhibit the production of both Insulin Growth Factor Binding Protein -2 and -5 (IGFBP-2, IGFBP-5) for the treatment of cancer.

  • Increased IGFBP-2 or IGFBP-5 production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, pancreatic, colon, AML, ALL, glioma, neuroblastoma, and melanoma.
  • Increased IGFBP-2 or IGFBP-5 production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration in humans.
  • Pre-clinical studies conducted by the Vancouver Prostate Centre and others in human prostate, bladder, glioma and breast cancer, have shown that reducing IGFBP-2 and IGFBP-5 production with OGX-225 sensitized these tumor types to hormone ablation therapy or chemotherapy and induced tumor cell death.